It was Albert Einstein who once said, "Any intelligent fool can make things bigger and more complex... It takes a touch of genius --- and a lot of courage to move in the opposite direction."
Years ago, the leadership team at a small but innovative firm in a northern suburb of Atlanta, Georgia, knew they had to set off in that direction.
Their technology was nothing new. In fact, Shock wave devices, which utilize acoustic pressure waves, had been used in urology to break up stones in the kidney, bladder, or ureter for about 30 years. In the last decade, however, the technology gained FDA approval to provide non-surgical alternatives for treating severe heel pain (chronic plantar fasciitis) and other chronic conditions like tennis elbow (epicondylitis).
The company owned the rights to the effective, but bulky OssaTron-- the first shock wave unit developed especially for those types of orthopedic applications. They were fully aware that the same technology had been shown in Europe to promote healing in several wound-healing applications. Management wanted to go after the multi-billion dollar market opportunities available in wound care markets like those in the diabetic foot ulcer treatment space, but they knew that in order to best commercialize and seek the full potential of this technology, they were going to have to make the device smaller, smarter and more accessible to patients; especially to those who were not responding to traditional wound healing procedures, and the physicians who look after them.
As a result, SANUWAVE Health (OTCBB:SNWV) is now positioned to become one of the leaders in the emerging field of regenerative medicine- not by harvesting or employing stem cells or creating living tissues, but by using a highly effective, non-invasive medical devices which have been perfected to activate a biological response for the repair and regeneration of tissue, musculoskeletal and vascular structures.
SANUWAVE’s patented medical device technologies are set to address multiple large healthcare markets, exceeding $10 billion in total. In fact, the disruptive technology appears ready to challenge the current standard of care leader whose competitive product generates >$1B in U.S. revenues.
Click Image Below To Read
The company has just submitted to the U.S. Food and Drug Administration (FDA) the third and final module of its Premarket Approval (PMA) application for their dermaPACE® device for the treatment of diabetic foot ulcers (DFU). This submission contained the PMA application, data from the Company’s recently completed pivotal Phase III, Investigational Device Exemption (IDE) clinical trial, proposed product labeling, and a summary of safety and effectiveness. (See: News Release About FDA Submission )
Given the superior trial design, several Wall Street Analysts who follow the company firmly believe that the strong data which was submitted will result in a positive response and approval from U.S. regulators.
Adding to the positive sentiment, the company has just announced that the American Medical Association (AMA) has released two Current Procedural Terminology (CPT) Category III codes for Extracorporeal Shock Wave Technology (ESWT) in wound healing: 0299T and 0300T.
Pending approval by the FDA of their Premarket Approval (PMA) application, SANUWAVE’s dermaPACE® would be the first and only ESWT device in the U.S. capable of utilizing these codes.
CPT Category III codes are a set of tracking codes established by the AMA that permit data collection for emerging technology, services and procedures such as dermaPACE®, which has been submitted to the FDA as a treatment for diabetic foot ulcers (DFU). The new codes were released on July 1, 2011 and will be implemented on January 1, 2012.
At least two analysts have been calling for the stock to out-perform the market, but their advice has been lost in the shuffle of today’s volatile markets and has fallen on deaf ears.
We believe the firm’s strong, yet very conservative management team has been very busy developing and readying the product for U.S. commercialization, but will become more aggressive in telling SANUWAVE's story. Officials from have begun showing up at conferences, and will continue presenting their data and company to both the medical and investment communities. The company also recently announced that their second quarter revenues increased by 40% and that they had achieved a number of important milestones in support of their goal of commercializing dermaPACE® in wound healing.
By multiple measures, the stock appears to be extremely undervalued and given their extremely low float (only 20.9 million shares outstanding), now appears poised ready for a run. Like the other analysts who have already assigned price targets, we would expect at least a double from the current price levels with more volume and price movement as we get closer to the actual FDA approval date.
In a recent coverage report dated August 19, Laura S. Engel, CPA of Stonegate Secutiries says a DCF (discounted cash flow) model shows a valuation range of approximately $5.31 - $6.79/share with the mid-point of the range at approximately $5.99. She also underscores the importance of SANUWAVE’s intellectual property portfolio which is currently comprised of over 50 issued and pending patents surrounding its PACE® technology. The portfolio covers a broad range of methods of use, technologies, and devices for treating a variety of specific and non-specific medical conditions with acoustic pressure waves in the high energy “shockwave” spectrum. SANUWAVE’s management plan calls for the company to go after multiple, large U.S. markets, exceeding $10 billion in total.
Until then, the task at hand involves going after patients experiencing chronic wounds with the technology (see the slide below). The market presents a growing problem which is rising significantly as the U.S. population ages. The latest figures indicate that 27 million people in the U.S. have diabetes and that 79 million are pre-diabetic. That members of that group report having in excess of 1.5 million diabetic ulcers annually and that 25% of diabetics will acquire a non-healing ulcer in their lifetime are compelling figures that foreshadow just how important this treatment technology might become.
Based on the totality of the available data set from the most recent clinical trials and the rigorous design, Analyst Suraj Kalia, CFA of Rodman & Renshaw says “we cannot help but think that dermaPACE® ‘could’ significantly cut down on treatment times, therefore presenting a compelling cost-effectiveness value proposition.” He adds, “If and when approved, this will be the first device-based therapy with a PMA approval. Even a 4 – 5% market share gain could yield revenues north of $80 million over the next 5 years.”
Good stock market information about market movers can be hard places to learn how to buy stock or how to trade. When new investors are looking for market tips and analysis, their stock selection process-- whether it be small cap, large cap, mid cap, micro cap or even small mid cap-- can be based on message board postings, stock market forums, or free tips. Equity tips from a penny stock guru or hot stock forums can be very dangerous.If you find stock market equity shares from jim cramer stock picks or trading on the stock market by using free stock search, stocks and share, mid cap growth stocks, small capitalization stocks, 50 cent penny stock, small caps stocks an stocks which are stocks under 5 dollars on how buy shares, then you may find small cap news makers which stocks under 5 stay under $5. Smart stocks include stock market bulls, stock market ideas and micro cap mutual funds to get share market basics, best stock information and small cap recommendations. deciding how to by shares can be hard. A stock market alert, is not a good tutorials on stock market or tutorials on share market. I'd say unless you're a hedge fund manager in charge of small cap funds who is getting pitched by company represenatives themselves, most of the best stock ideas are really hard to come by. The Unites States stock market is full off micro-cap values and best stock ideas, but if you're playing the over the counter game, you have to be careful of junk stocks which are the . If you're not sure, stick to the dow jones,nyse, and others which are national stock exchange members. Setting your market watch is imporant and stocks. Don't be afraid to use otcbb equity research, medical device news, biotechnology news, penny stock quotes, stock market quotes, stock market index, stock analysis and intraday information as small cap investment tools. Shorting stock can also be dangerous. Small cap value stocks are hard to find. The current stock market, stock lists and technical analysis of stocks can take time to really appreciate and information on stock market and decipher. Investing school can help you figure out exactly what are stocks, stock market profit, stock market volume, equity markets, biotechnology industry news, and definition penny stock. You have to be aware that new stocks can be tricky and that stock market management, nse stock tips, good small cap stocks, stock market hot stocks, stocks under 1, cap companies and market caps. Canadian small cap trading how to and all about the stock market is great penny stock picks! search for stocks not allpennystocks or shares in stock much less micro cap funds, micro cap market, micro cap news or even the definition of penny stock. Large capitalization stocks may be where you want to stay especially given these bulls and bears in stock market. Stay away expecially from pink stock market, stockpickr may disagree but share securities, news for stock market, intra day tips, penny stock success stories and micro cap value can be found in places like idea stock price, best stock market strategies and us stock market today.This has been a killer penny stocks review for stock pickr and msn stock market today in association with intraday free tips and meaning stock market.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites